Janssen

CARVYKTI

Manufacturer:

Janssen

Carvykti HCPCS:

Q2056

HCPCS Code Descriptor:

Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Category:

Q Code

Carvykti NDCs:

57894-0111-01, 57894-0111-02

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Bag

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

57894-0111-01, 57894-0111-02

About Carvykti:

CARVYKTI is an Oncology drug manufactured by Janssen and administered via the Intravenous route of administration. The Q Code: Q2056 is aligned to the drug CARVYKTI.

ACCESS PRICING AND MORE BY REGISTERING

Q2056 Added Date:

October 1, 2022

Q2056 Effective Date:

October 1, 2022

Q2056 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Carvykti billing and coding information.
Carvykti patient assistance information can be found through The MyCARVYKTI® Patient Support Program at the URL: https://www.carvykti.com/resources-and-support
CARVYKTI prescribing information can be found at the link below:
Information regarding CARVYKTI’s side effects can be found at MedlinePlus